Advanced Human Imaging (ASX:AHI) - CEO and Chairman, Vlado Bosanac
CEO and Chairman, Vlado Bosanac
Source: AHI
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Advanced Human Imaging (AHI) enters the Estonian market after signing a binding term sheet with digital health provider Activate Health OÜ
  • Activate Health is an all-in-one solution for optimising health to expand the human lifespan with its platform including medical-grade health audits, targeted micro-programs, science-backed recommendations and on-demand coaching
  • Currently, it is building a digital therapeutics platform for the prevention and early intervention of metabolic syndrome
  • The term sheet will see Activate Health integrate AHI’s body scanning solution and comes after Activate conducting a successful trial of the AHI CompleteScan application
  • AHI is up 1.63 per cent on the market with shares trading at 62.5 cents

Advanced Human Imaging (AHI) has entered the Estonian market after signing a binding term sheet with digital health provider Activate Health OÜ.

Activate Health is an all-in-one solution for optimising health to expand the human lifespan.

Its platform features medical-grade health audits, targeted micro-programs, science-backed recommendations and on-demand coaching.

Currently, it is building a digital therapeutics platform for the prevention and early intervention of metabolic syndrome.

In January 2022, Activate Health was awarded a €1.05 million (A$1.66 million) grant from Enterprise Estonia to expand its digital health footprint.

“We are extremely excited to be working with AHI and to integrate their solution into the Activate platform application,” Activate Health Founder and CEO Siim Saare said.

“Furthermore, we are elated to have received a grant from Enterprise Estonia Applied Research Programme to further develop the Activate platform together with the Estonian Genome Centre, University of Tartu and SYNLAB.”

The term sheet will see Activate Health integrate AHI’s body scanning solution with all commercial agreements to be concluded within 30 days.

This follows Activate conducting a successful trial of the AHI CompleteScan application.

“Siim and his team have been great to work with and moved very quickly to consummate a term sheet with AHI once they had the opportunity to use the technology and see how well it performs,” AHI CEO Vlado Bosanac commented.

“The AHI MultiScan digital health solution will empower the Activate platform with the ability to identify chronic disease risk, for the early intervention, allowing Activate to intervene and assist their consumers with better health outcomes.”

AHI was up 1.63 per cent on the market with shares trading at 62.5 cents by the end of the trading day.

AHI by the numbers
More From The Market Herald
IGO (ASX:IGO) - CEO & Managing DIrector, Peter Bradford

" IGO (ASX:IGO) produces first battery-grade lithium hydroxide from Kwinana refinery

IGO (ASX:IGO) has produced the first battery-grade lithium hydroxide from the Kwinana Lithium Hydroxide Refinery in…

" Seafarms (ASX:SFG) appoints Rod Dyer as CEO among executive changes

Seafarms (ASX:SFG) has appointed Rod Dyer as CEO, effectively immediately.
Recce Pharmaceuticals (ASX:RCE) - Chief Executive Officer, James Graham

" Recce Pharmaceuticals’ (ASX:RCE) clinical trial returns positive safety profile

Recce Pharmaceuticals (ASX:RCE) has seen its clinical trial receive a good safety profile among ten healthy…

" Althea (ASX:AGH) enters Irish medicinal cannabis market

Althea (ASX:AGH) has received approval from the Health Products Regulatory Authority (HPRA) for its CBD12:THC10 product…